KR20110015409A - 염증성 장 질환에 대한 유전자 발현 마커 - Google Patents

염증성 장 질환에 대한 유전자 발현 마커 Download PDF

Info

Publication number
KR20110015409A
KR20110015409A KR1020107014096A KR20107014096A KR20110015409A KR 20110015409 A KR20110015409 A KR 20110015409A KR 1020107014096 A KR1020107014096 A KR 1020107014096A KR 20107014096 A KR20107014096 A KR 20107014096A KR 20110015409 A KR20110015409 A KR 20110015409A
Authority
KR
South Korea
Prior art keywords
ibd
expression
seq
genes
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107014096A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 알. 아바스
힐러리 클락
로리 디엘
찰스 리스
콜린 엘. 노블
잭 사트상기
Original Assignee
제넨테크, 인크.
더 유니버시티 코트 오브 더 유니버시티 오브 에딘버그
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2008/064562 external-priority patent/WO2008147900A2/en
Application filed by 제넨테크, 인크., 더 유니버시티 코트 오브 더 유니버시티 오브 에딘버그 filed Critical 제넨테크, 인크.
Publication of KR20110015409A publication Critical patent/KR20110015409A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107014096A 2007-11-29 2008-11-26 염증성 장 질환에 대한 유전자 발현 마커 Ceased KR20110015409A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US99120307P 2007-11-29 2007-11-29
US60/991,203 2007-11-29
PCT/US2008/064562 WO2008147900A2 (en) 2007-05-22 2008-05-22 Gene expression markers for inflammatory bowel disease
WOPCT/US2008/064562 2008-05-22
US19226808P 2008-09-17 2008-09-17
US61/192,268 2008-09-17

Publications (1)

Publication Number Publication Date
KR20110015409A true KR20110015409A (ko) 2011-02-15

Family

ID=40459795

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107014096A Ceased KR20110015409A (ko) 2007-11-29 2008-11-26 염증성 장 질환에 대한 유전자 발현 마커

Country Status (9)

Country Link
EP (1) EP2261367A3 (enExample)
JP (1) JP2011509071A (enExample)
KR (1) KR20110015409A (enExample)
CN (1) CN101970689A (enExample)
AU (1) AU2008334095A1 (enExample)
CA (1) CA2706729A1 (enExample)
IL (2) IL206014A (enExample)
MX (1) MX2010005893A (enExample)
WO (1) WO2009073565A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101394197B1 (ko) * 2012-08-17 2014-05-30 관동대학교산학협력단 염증성 장 질환과 연관된 단일염기다형성 정보를 제공하는 방법

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010276392A1 (en) * 2009-07-20 2012-03-08 Genentech, Inc. Gene expression markers for Crohn's disease
EP2486130A1 (en) * 2009-10-06 2012-08-15 Tallinn University Of Technology Inhibition or activation of serine/threonine ulk3 kinase activity
WO2011127351A1 (en) * 2010-04-09 2011-10-13 Exagen Diagnostics, Inc. Biomarkers for ulcerative colitis and crohn's disease
EP2576838A4 (en) * 2010-06-04 2019-05-15 Nestec S.A. METHOD FOR IMPROVING DIAGNOSIS OF INFLAMMATORY ENDURANCE
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CN103336914B (zh) * 2013-05-31 2016-05-25 中国人民解放军国防科学技术大学 一种提取荟萃生物标志物的方法及装置
EP3736340A1 (en) * 2014-08-28 2020-11-11 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth Methods and kit for identification of cancer
JP6192177B2 (ja) * 2015-05-25 2017-09-06 ヤマサ醤油株式会社 炎症性腸疾患のバイオマーカーとしてのｓ１００ａ９の使用
JP7082945B2 (ja) * 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
CA3056911A1 (en) * 2017-03-23 2018-09-27 Meharry Medical College Methods for diagnosing and treating inflammatory bowel disease
CA3067397A1 (en) * 2017-06-20 2018-12-27 Meharry Medical College Targeted defa5 antibody and assay methods for diagnosing and treating inflammatory bowel disease
EP3774848B1 (en) * 2018-03-29 2023-02-22 Lateral Ip Pty Ltd Cyclic peptides and uses thereof
CN110577953B (zh) * 2018-06-11 2024-02-20 深圳华大生命科学研究院 基因突变体及其应用
CN108893488A (zh) * 2018-06-19 2018-11-27 刘志强 一种重组质粒、dna疫苗及其制备方法和应用
WO2020000436A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种特异靶向人INDO基因的gRNA导向序列及其应用
EP3821246A4 (en) * 2018-07-15 2022-06-22 Rambam Med-Tech Ltd. Determining responders to inflammation treatment
CN110241116B (zh) * 2019-05-21 2023-02-07 中国医学科学院放射医学研究所 一种环状rna及在促进dna损伤修复中的应用
US12293809B2 (en) 2019-08-23 2025-05-06 Insilico Medicine Ip Limited Workflow for generating compounds with biological activity against a specific biological target
JP2021185817A (ja) * 2020-05-29 2021-12-13 独立行政法人国立病院機構 バイオマーカー及びインターフェロンγ関連遺伝子のバイオマーカーとしての使用
WO2025029562A1 (en) * 2023-07-28 2025-02-06 The Johns Hopkins University Dna vaccines for eliciting t cell immunity in the lung
CN119236059B (zh) * 2024-10-11 2025-04-18 广东医科大学附属医院 Pdlim4基因在制备抑制非小细胞肺癌增殖的药物中的应用
CN119798401B (zh) * 2024-12-30 2025-10-10 常州因普迈生物科技有限公司 基于pdzk1ip1蛋白的多肽、抗体及其应用
CN120510912A (zh) * 2025-05-20 2025-08-19 北京大学人民医院 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DK0527283T3 (da) 1991-08-12 1998-08-10 Nestle Sa Levnedsmiddelsammensætning
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2223198A1 (en) 1997-01-14 1998-07-14 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
MXPA01008936A (es) * 1999-03-04 2003-07-21 Human Genome Sciences Inc Receptores 6 alfa y 6 beta del factor de necrosis tumoral.
EP1287162A2 (en) * 1999-10-21 2003-03-05 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP1844158A4 (en) * 2004-12-06 2010-09-08 Univ Johns Hopkins BIOMARKER FOR INFLAMMATORY ENDURANCE
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
AU2009215441B2 (en) * 2008-02-19 2015-07-02 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101394197B1 (ko) * 2012-08-17 2014-05-30 관동대학교산학협력단 염증성 장 질환과 연관된 단일염기다형성 정보를 제공하는 방법

Also Published As

Publication number Publication date
CN101970689A (zh) 2011-02-09
AU2008334095A1 (en) 2009-06-11
JP2011509071A (ja) 2011-03-24
AU2008334095A2 (en) 2010-07-15
MX2010005893A (es) 2011-03-04
EP2261367A2 (en) 2010-12-15
EP2261367A3 (en) 2011-03-23
IL206014A (en) 2014-07-31
IL233432A0 (en) 2014-08-31
IL206014A0 (en) 2010-11-30
WO2009073565A2 (en) 2009-06-11
WO2009073565A3 (en) 2009-09-24
CA2706729A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
KR20110015409A (ko) 염증성 장 질환에 대한 유전자 발현 마커
AU2019201577B2 (en) Cancer diagnostics using biomarkers
AU2017235661B2 (en) Oligonucleotide probes and uses thereof
AU2015334841B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
KR101545020B1 (ko) 식도암 및 식도암 전이 진단을 위한 조성물 및 방법
DK2471954T3 (en) Susceptibility genetic variants associated with cardiovascular diseases
CN101874120B (zh) 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型
AU2016331663B2 (en) Pathogen biomarkers and uses therefor
US20190300967A1 (en) Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
AU2015257483B2 (en) Biomarkers and combinations thereof for diagnosising tuberculosis
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
WO2003042661A2 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
KR20150090246A (ko) 암을 위한 분자 진단 테스트
KR20110036608A (ko) 유방암 위험도 평가를 위한 유전적 변이
KR20160117606A (ko) 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험
KR102016006B1 (ko) 교모세포종의 진단 또는 예후 예측용 바이오마커 및 그 용도
CN113383085A (zh) 用于分析核酸分子的方法和系统
KR20140140069A (ko) 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법
US20200300859A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
KR20060045950A (ko) 혈액학적 악성종양에 대한 예후
BR112020000791A2 (pt) métodos para detecção de discrasia de célula plasmática
US12478665B2 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
KR20070099564A (ko) 급성 골수성 백혈병 환자를 평가하는 방법
US20020137077A1 (en) Genes regulated in activated T cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100625

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131126

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150521

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150930

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150521

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I